Sanofi has launched a website to raise awareness of a relatively new discovery about multiple sclerosis (MS). Researchers have defined a second form of disease progression, which is more gradual, despite relapses and MRIs appearing to be stable – called “chronic smoldering.” The “Rediscover MS” website aims to expand understanding of disease progression in the MS community to include information about not only the physical symptoms, but also the cognitive and emotional symptoms. It also wants to help redefine what stability means. Learn more: https://hubs.la/Q02SPF8S0 #multiplesclerosis #ms #medicaleducation #diseaseawareness
H1
Software Development
New York, NY 17,572 followers
H1 is the connecting force for global HCP, clinical, scientific and research information.
About us
At H1, our mission is nothing short of creating a healthier future worldwide by unlocking and democratizing global access to critical expertise, HCP information, claims data, ground-breaking research and discoveries, and connected insights for all – doctors, researchers, industry and, ultimately, patients – bringing everyone closer together to advance medicine and clinical outcomes. Insights derived from H1’s solutions help life sciences and other healthcare organizations accelerate the development, launch, and dissemination of life-saving treatments, drive meaningful engagements with key opinion leaders, and help ensure equitable access to healthcare services.
- Website
-
https://h1.co
External link for H1
- Industry
- Software Development
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2017
- Specialties
- healthcare, provider data, healthcare professional information, diversity data, medical affairs, pharmaceutical, data science, medical science liaison, msl education, key opinion leaders, kol mapping, biotechnology, life sciences, healthcare data, HCPs, SaaS, healthcare content, clinical trials, clinical operations, and global drug development
Locations
-
Primary
373 Park Ave S
4th Floor
New York, NY 10016, US
Employees at H1
Updates
-
Underperforming or non-performing sites are a common challenge in clinical research. Clinical trial failures often occur when studies are unable to meet patient enrollment goals. Considering the rising cost of bringing new drugs to market, sponsors and CROs must explore new avenues to address these challenges. H1 offers the industry’s first-ever AI-powered Site Rescue functionality to recommend which HCPs and sites can help when a trial site is struggling. With Nearby Sites, you can quickly find viable locations nearby to support or replace underperforming sites, saving both time and money, and ensuring your trial stays on track. Learn more: https://hubs.la/Q02SWp0V0 #clinicaltrials #siterescue #patientenrollment #underenrollment
-
In recognition of #BreastCancerAwareness month, we’re sharing below some statistics from the H1 platform that give a glimpse into treatment and research in this field. #BreastCancer impacts women regardless of race and age, with the 60- to 70-year-old population being most at risk. All women 40 and over should seek proactive care and get regular mammograms. Find out how you can gain access to insights like these with Trial Landscape: https://hubs.la/Q02SWwrK0 #thinkpink #cancersupport #fightbreastcancer
-
During National Physician Assistant Week 2024, we want to recognize PAs for all of the incredible work they do to treat and care for patients. PAs play a crucial part in patient education, chronic care management, prescribing medications, and more. As such, these HCPs have a profound opportunity to help shape the future of healthcare. H1 has insights on more than 180,000 PAs to help you find and connect with the right professionals. Learn more: https://hubs.la/Q02SFmmX0 #nationalphysicianassistantweek #paweek #physicianassistants #hcps #hcpdata
-
MedTech kicks off next week! H1’s Chris Gardella, SVP Commercial and Kyle Horton, Account Executive will be at #MTC24 to support medical device companies as they prepare to meet FDA guidance on Diversity Action Plans. Want to see how other med device companies are using H1 to support FDA diversity planning? Connect with Chris and Kyle to see how H1 empowers medical device sponsors to find diverse sites and patients for more equitable clinical trials. Hope to see you there! https://hubs.la/Q02Sx-wn0 #medtech #healthequity #clinicaltrialdiversity #equitablecare #healthcareinnovation
-
As the scope of Medical Affairs continues to evolve, so does the need to be able to effectively measure the impact of their outreach efforts. Traditional measurements of pharma success, like sales and script volumes, are not things MSLs directly influence. While some subjective measurements can be made related to activity metrics and advocacy scoring, these metrics miss the full picture of Medical Affairs contributions – which should include not only quantity but quality of interactions, including influence on clinical practices. Learn more: https://hubs.la/Q02Sl7Ws0
-
Bristol Myers Squibb has received a momentous approval from the FDA for a new antipsychotic drug to treat patients with schizophrenia. Unlike available antipsychotics that work to balance dopamine or serotonin levels, Cobenfy activates “muscarinic receptors” to harmonize certain brain circuits. While there are concerns about adoption and insurance coverage, clinical trials showed that the drug significantly relieved schizophrenia symptoms without some of the side effects common to other antipsychotics. Learn more: https://hubs.la/Q02RFGny0 #schizophrenia #bms #bristolmyerssquibb #antipsychotics #mentalhealth
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
biopharmadive.com
-
Find out how clinical trial sponsors are preparing to follow the new FDA guidance on diversity action plans and how technology solutions can support this effort. Our 2024 report into the State of Diversity and Equity in Clinical Trials identifies the latest developments and strategic insights that are critical for enhancing clinical trial diversity. Download here: https://hubs.la/Q02S24L10 #healthequity #clinicaltrialdiversity #patientrepresentation #diversityinclusion
-
In times of crisis, mobilizing resources efficiently can be the difference between life and death. Technology offers a powerful tool to cut through the red tape to focus on what truly matters—saving lives. In his new article for Forbes Technology Council, our CEO Ariel Katz highlights how harnessing innovative technologies can be pivotal to transcending the limitations of politics and policy during times of need. Read more here: https://hubs.la/Q02RTswm0 #HumanitarianEfforts #MedicalAid
Council Post: Using Technology For Good: Improving Humanitarian Efforts Through Innovation
social-www.forbes.com
-
Will you be attending The MedTech Conference in a couple of weeks? H1’s Chris Gardella, SVP Commercial and Kyle Horton, Account Executive will be at #MTC24 to support medical device companies as they prepare to meet FDA guidance on Diversity Action Plans. Would it benefit you to see how other med device companies are using H1 to support FDA diversity planning? Connect with Chris and Kyle to see how H1 empowers medical device sponsors to find diverse sites and patients for more equitable clinical trials. Hope to see you there! https://hubs.la/Q02RJlfQ0 #medtech #healthequity #clinicaltrialdiversity #equitablecare #healthcareinnovation